26 results match your criteria: "Columbia University Division of Cardiology at Mount Sinai Medical Center[Affiliation]"
Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.
Circulation
January 2014
Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (S.S.M., M.J.B., P.O., S.R.J., R.S.B., K.N.); Noninvasive Cardiovascular Imaging Program, Department of Medicine (Cardiovascular Division) and Radiology, Brigham and Women's Hospital, Boston, MA (R.B.); South Beach Preventive Cardiology Center, University of Miami, Miami, FL (A.A.); Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, FL (J.J.R.); Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX (S.S.V.); Division of Cardiology, Harbor-University of California Los Angeles Medical Center, Los Angeles, CA (M.J.B.); Center for Prevention and Wellness Research, Baptist Health Medical Group, Miami, FL (K.N.); Baptist Cardiovascular Institute, Baptist Health South Florida, Miami, FL (K.N.); Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, FL (K.N.); and Department of Medicine, Herbert Wertheim College of Medicine, Miami, FL (K.N.).
Background: Worldwide clinical practice guidelines for dyslipidemia emphasize allocating statin therapy to those at the highest absolute atherosclerotic cardiovascular disease (CVD) risk.
Methods And Results: We examined 5534 Multi-Ethnic Study of Atherosclerosis (MESA) participants who were not on baseline medications for dyslipidemia. Participants were classified by baseline coronary artery calcium (CAC) score (>0, ≥ 100) and the common clinical scheme of counting lipid abnormalities (LA), including low-density lipoprotein cholesterol ≥ 3.